Dr. Abou-Alfa on Significance of RESORCE Trial for HCC

Ghassan K. Abou-Alfa, MD
Published: Tuesday, Jul 26, 2016


Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma (HCC) who progressed after receiving sorafenib (Nexavar).

The RESORCE study is important for the HCC field because it demonstrates that patients have a promising option in the second-line treatment setting, Abou-Alfa explains.

This trial shows encouraging findings compared with prior studies, in which the placebo arms performed better in experimental arms, he adds.
 

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma (HCC) who progressed after receiving sorafenib (Nexavar).

The RESORCE study is important for the HCC field because it demonstrates that patients have a promising option in the second-line treatment setting, Abou-Alfa explains.

This trial shows encouraging findings compared with prior studies, in which the placebo arms performed better in experimental arms, he adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x